These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 8677457)

  • 1. Oral administration of mesna with ifosfamide.
    Goren MP
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
    Goren MP; McKenna LM; Goodman TL
    Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    Cohen MH; Dagher R; Griebel DJ; Ibrahim A; Martin A; Scher NS; Sokol GH; Williams GA; Pazdur R
    Oncologist; 2002; 7(5):393-400. PubMed ID: 12401901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP; Epelman S; Bush DA
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Olver I; Keefe D; Myers M; Caruso D
    Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
    Matsumoto S; Kawaguchi N; Manabe J; Kuroda H; Shimoji T
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):965-8. PubMed ID: 7794006
    [No Abstract]   [Full Text] [Related]  

  • 9. Nursing implications in the administration of ifosfamide and mesna.
    Richters JE
    Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
    [No Abstract]   [Full Text] [Related]  

  • 10. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
    Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
    Korkmaz A; Oter S; Deveci S; Goksoy C; Bilgic H
    J Urol; 2001 Sep; 166(3):1119-23. PubMed ID: 11490309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
    Dornelas-Filho AF; Pereira VBM; Wong DVT; Nobre LMS; Melo AT; Silva CMS; Wanderley CWS; Nour ML; Araújo LCNC; Silva RO; Pinto FMM; Bingana RD; Souza MHLP; Alencar NMN; Silva PGB; Alves APNN; Almeida PRC; Cunha FQ; Lima-Júnior RCP
    Int Immunopharmacol; 2018 Sep; 62():96-108. PubMed ID: 29990699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
    Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of ketamine against hemorrhagic cystitis in rats receiving ifosfamide.
    Ozguven AA; Yılmaz O; Taneli F; Ulman C; Vatansever S; Onag A
    Indian J Pharmacol; 2014; 46(2):147-51. PubMed ID: 24741183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
    Frustaci S; Foladore S; De Pascale A; Freschi A; Lo Re G; Sorio R; Errante D; Monfardini S
    Ann Oncol; 1992 Apr; 3 Suppl 2():S115-8. PubMed ID: 1622852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
    J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide and mesna.
    Med Lett Drugs Ther; 1989 Nov; 31(804):98-9. PubMed ID: 2554100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.